Latest Issue

Volume 22 Issue 2

Paper of the Month

Progesterone receptor is a significant factor associated with clinical outcomes and effect of adjuvant tamoxifen therapy in breast cancer patients.

Liu S, Chia SK, Mehl E et al.
Recent guidelines from the National Institute for Health and Clinical Excellence in the UK on the treatment of early stage breast cancer clearly recommend that progesterone receptor (PR) assessment need no longer be routinely performed in cases of early stage breast cancer.
» Read an expert review of this paper

Webcast

Tamoxifen Use and Second Breast Cancers
Christopher Li, MD PhD, (Associated member, Public Health Sciences Division, Fred Hutchinson Cancer Research Center) discusses tamoxifen use and second breast cancers.


Our most popular articles

Latest news

  • Home
  • Home
  • Home
  • Home
  • Home
  • Home

READER POLL

Breast Cancer Poll 1
What approach do you currently use for the treatment of patients with HER2-overexpressing metastatic breast cancer whose disease has progressed despite trastuzumab?






Powered by NetPolls
CLOSE
Your First Name

Your Surname

Recipient's Email Address *

To automatically send an email containing a link to this page, please enter the recipient's email address and your name (optional).

READER SURVEY

SUBMIT AN ARTICLE

OTHER REMEDICA JOURNALS

COMPASS PUBMED SEARCH

Enter your search terms below to search pubmed for articles